Mario serves as Chairman of Orthonika, having previously led the company as CEO since formation. He is one of the key inventors behind the technology. Previously, Mario was a venture capitalist, most recently as a Venture Partner with Fort Rock Capital where he served on the Boards of vasopharm GmbH and GNS Healthcare. Prior to that he was part of the life sciences investment team at Entrepreneurs Fund whose notable investments include Optinose (listed on the Nasdaq) and Prosonix (acquired by Circassia).  Mario started his career in strategy consulting with Deallus Consulting.

Mario holds a Postgraduate in Genomic Medicine, a Ph.D. in Biomedical Engineering and a First-Class Honours MEng Degree in Mechanical Engineering with a focus on Biomedical, all from Imperial College London. Mario’s academic research focused on early diagnosis of osteoarthritis, regenerative medicine techniques and orthopaedic biomechanics. He is an inventor in several patents and has published in international peer reviewed scientific journals. Mario is also CEO and Co-Founder of Orexia Therapeutics (merged with Centessa Pharmaceuticals, NASDAQ: CNTA) and serves on the Board of Embody Orthopaedics and on the Strategic Advisory Board of G3 Therapeutics.